Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 53Ovarian Neoplasms 4Prostatic Neoplasms 3Neoplasms 3Inflammatory Breast Neoplasms 3HER2-positive Breast Cancer 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Solid Tumor 2Rectal Neoplasms 2Neoplasm Metastasis 2Colonic Neoplasms 2Urinary Bladder Neoplasms 1Solid Cancers 1Patient Preference 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms, Unknown Primary 1Multiple Endocrine Neoplasia 1Malignant Solid Neoplasm 1Lung Neoplasms 1Locally Advanced Breast Cancer 1Her2-Positive Breast Cancer 1HER2-positive Metastatic Breast Cancer 1HER2-positive Early Breast Cancer 1HER2-Positive Early Breast Cancer 1HER2 Positive Breast Cancer 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1

Interventions

Prednisone 112Docetaxel 87Leuprolide 79enzalutamide 72Abiraterone Acetate 67bicalutamide 53Goserelin 50acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 42Radiotherapy 39abiraterone 28Magnetic Resonance Spectroscopy 27Gonadotropin-Releasing Hormone 24gallium 68 PSMA-11 23apalutamide 22Androgen Antagonists 22luprolide acetate gel depot 21sipuleucel-T 20Radiosurgery 20Triptorelin Pamoate 18cabazitaxel 17cabozantinib 16Radiotherapy, Intensity-Modulated 16Flutamide 16pembrolizumab 15radium Ra 223 dichloride 14Prednisolone 14Nivolumab 14Dutasteride 14Dexamethasone 14Radiation 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Prostatic Neoplasms × pertuzumab × Clear all
NCT05730712 2026-05-15

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Mayo Clinic

Phase 2 Completed
7 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT02480010 2015-09-18

A Study of Pertuzumab in Participants With Prostate Cancer

Hoffmann-La Roche

Phase 2 Terminated
68 enrolled 18 charts
Genitourinary

Prostatic Neoplasms

NCT00058539 2015-06-23

Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer

Genentech, Inc.

Phase 2 Completed
42 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡